Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses how the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) compared with other EGFR inhibitors for patients with

As a third-generation EGFR inhibitor, osimertinib is very specific for EGFR compared with other EGFR inhibitors. The tolerability profile is also more favorable because osimertinib has fewer effects on the wildtype

Osimertinib also has better CNS penetration than the other EGFR TKIs. Research has shown that 40% to 45% of patients with

mutations will develop brain metastases during the course of their disease at some point, so having an agent like osimertinib which has better CNS penetration is important. Finally, Ramalingam says that osimertinib can inhibit T790M, in addition to exon 19 and exon&nbsp;

For more information from Ramalingam on osimertinib in

https://www.targetedonc.com/news/updated-flaura-data-support-fda-approval-of-osimertinib-in-egfr-nsclc

Videos

Suresh S. Ramalingam, MD, discusses how the EGFR tyrosine kinase inhibitor osimertinib compared with other EGFR inhibitors for patients with&nbsp;EGFR-mutant lung cancer.

Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of treating brain metastases in

-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

In the FLAURA trial, presented at the 2019 European Lung Cancer Congress, osimertinib showed intracranial responses.

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in <em>EGFR</em>-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.

Hsp90 is a rational targeted for cancer since a number of oncoproteins depend on the associate of Hsp90 in order to become active.

The drug ganetespib has now been combined with chemotherapy in randomized trials as a potential treatment option for lung cancer.

GALAXY-2, a phase III trial, will randomize patients to docetaxel with or without ganetespib.

Hsp90 as Potential Treatment for Lung Cancer

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses data presented at the 2014 ASCO Annual Meeting examining EGFR inhibitors for lung cancer.

Articles

New Data for EGFR Inhibitors for Lung Cancer

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses the investigation of the heat shock protein (Hsp) 90 inhibitor ganetespib as a treatment for patients with advanced lung cancer.

Heat shock proteins chaperone newly formed proteins to become structurally active and perform their biologic function, Ramalingam notes. Blocking this process by the inhibition of Hsp90 with an agent like ganetespib renders these new proteins inactive. Altogether, Ramalingam notes, there are over 200 known proteins associated with Hsp90, many of which are important to the development of lung cancer, including EGFR and ALK.

The promise with ganetespib is that by inhibiting Hsp90, multiple oncoproteins that fuel lung cancer would also be simultaneously inhibited. This theory was tested in the phase II GALAXY-1 trial that explored ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma. When compared to docetaxel, ganetespib improved overall survival by 2.4 months. Moreover, Ramalingam notes, these outcomes were more pronounced in patients diagnosed at least 6 months prior to treatment, with an overall survival improvement of 4.3 months.

As it stands, this is the first randomized trial to document efficacy for Hsp90 inhibition in cancer, Ramalingam suggests. If this remains true in a phase III trial there will be broad implications in other types of cancer.

Several proteins are associated with Hsp90, many of which are important to the development of lung cancer

The phase II GALAXY-1 trial explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma

In GALAXY-1, second-line ganetespib improved overall survival by 2.4 months longer than docetaxel

GALAXY-1 was the first randomized trial to document the efficacy of an Hsp90 inhibitor in cancer

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, discusses the investigation of the heat shock protein 90 inhibitor ganetespib as a treatment for patients with advanced lung cancer.

Suresh S. Ramalingam, MD | Authors

Articles

Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC

Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

Hsp90 as Potential Treatment for Lung Cancer

New Data for EGFR Inhibitors for Lung Cancer

Hsp90 Inhibition With Ganetespib as a Lung Cancer Treatment